

Delphine Merino

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6260004/publications.pdf>

Version: 2024-02-01

43
papers

2,826
citations

218677

26
h-index

361022

35
g-index

47
all docs

47
docs citations

47
times ranked

4655
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 1 | Differential Inhibition of TRAIL-Mediated DR5-DISC Formation by Decoy Receptors 1 and 2. <i>Molecular and Cellular Biology</i> , 2006, 26, 7046-7055. | 2.3 | 288 |
| 2 | Spatial omics and multiplexed imaging to explore cancer biology. <i>Nature Methods</i> , 2021, 18, 997-1012. | 19.0 | 279 |
| 3 | BH3-Mimetic Drugs: Blazing the Trail for New Cancer Medicines. <i>Cancer Cell</i> , 2018, 34, 879-891. | 16.8 | 250 |
| 4 | Targeting BCL-2 with the BH3 Mimetic ABT-199 in Estrogen Receptor-Positive Breast Cancer. <i>Cancer Cell</i> , 2013, 24, 120-129. | 16.8 | 243 |
| 5 | Bcl-2, Bcl-xL, and Bcl-w are not equivalent targets of ABT-737 and navitoclax (ABT-263) in lymphoid and leukemic cells. <i>Blood</i> , 2012, 119, 5807-5816. | 1.4 | 168 |
| 6 | The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. <i>Journal of Cell Biology</i> , 2009, 186, 355-362. | 5.2 | 164 |
| 7 | TRAIL in cancer therapy: present and future challenges. <i>Expert Opinion on Therapeutic Targets</i> , 2007, 11, 1299-1314. | 3.4 | 148 |
| 8 | Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer. <i>Science Translational Medicine</i> , 2017, 9, . | 12.4 | 148 |
| 9 | Targeting BCL-2 to enhance vulnerability to therapy in estrogen receptor-positive breast cancer. <i>Oncogene</i> , 2016, 35, 1877-1887. | 5.9 | 116 |
| 10 | Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer. <i>Nature Communications</i> , 2019, 10, 766. | 12.8 | 99 |
| 11 | Neoadjuvant neratinib promotes ferroptosis and inhibits brain metastasis in a novel syngeneic model of spontaneous HER2+ve breast cancer metastasis. <i>Breast Cancer Research</i> , 2019, 21, 94. | 5.0 | 87 |
| 12 | Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. <i>Leukemia</i> , 2014, 28, 1207-1215. | 7.2 | 79 |
| 13 | A mitochondrial block and expression of XIAP lead to resistance to TRAIL-induced apoptosis during progression to metastasis of a colon carcinoma. <i>Oncogene</i> , 2008, 27, 6012-6022. | 5.9 | 78 |
| 14 | Chemotherapy overcomes TRAIL-R4-mediated TRAIL resistance at the DISC level. <i>Cell Death and Differentiation</i> , 2011, 18, 700-711. | 11.2 | 75 |
| 15 | Dual inhibition of BCL-XL and MCL-1 is required to induce tumour regression in lung squamous cell carcinomas sensitive to FGFR inhibition. <i>Oncogene</i> , 2018, 37, 4475-4488. | 5.9 | 75 |
| 16 | Arsenic Trioxide Induces Apoptosis of Human Monocytes during Macrophagic Differentiation through Nuclear Factor- κ B-Related Survival Pathway Down-Regulation. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 316, 304-314. | 2.5 | 68 |
| 17 | TRAIL Induces Receptor-Interacting Protein 1-Dependent and Caspase-Dependent Necrosis-Like Cell Death under Acidic Extracellular Conditions. <i>Cancer Research</i> , 2007, 67, 218-226. | 0.9 | 62 |
| 18 | TRAIL-R4 Promotes Tumor Growth and Resistance to Apoptosis in Cervical Carcinoma HeLa Cells through AKT. <i>PLoS ONE</i> , 2011, 6, e19679. | 2.5 | 57 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | Apoptotic, necrotic, or fused tumor cells: An equivalent source of antigen for dendritic cell loading. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1513-1524. | 4.9 | 36 |
| 20 | The inhibition of TNF- α anti-tumoral properties by blocking antibodies promotes tumor growth in a rat model. Experimental Cell Research, 2007, 313, 2345-2355. | 2.6 | 35 |
| 21 | Alternative splicing of Bim and Erk-mediated BimEL phosphorylation are dispensable for hematopoietic homeostasis in vivo. Cell Death and Differentiation, 2012, 19, 1060-1068. | 11.2 | 32 |
| 22 | Targeting triple-negative breast cancers with the Smac-mimetic birinapant. Cell Death and Differentiation, 2020, 27, 2768-2780. | 11.2 | 31 |
| 23 | Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells. Journal of Experimental Medicine, 2011, 208, 1351-1358. | 8.5 | 29 |
| 24 | Breast tumour organoids: promising models for the genomic and functional characterisation of breast cancer. Biochemical Society Transactions, 2019, 47, 109-117. | 3.4 | 29 |
| 25 | The Bcl-2 family in autoimmune and degenerative disorders. Apoptosis: an International Journal on Programmed Cell Death, 2009, 14, 570-583. | 4.9 | 28 |
| 26 | Pro-apoptotic Bim suppresses breast tumor cell metastasis and is a target gene of SNAI2. Oncogene, 2015, 34, 3926-3934. | 5.9 | 27 |
| 27 | Impact of conditional deletion of the pro-apoptotic BCL-2 family member BIM in mice. Cell Death and Disease, 2014, 5, e1446-e1446. | 6.3 | 25 |
| 28 | The site of breast cancer metastases dictates their clonal composition and reversible transcriptomic profile. Science Advances, 2021, 7, . | 10.3 | 23 |
| 29 | Bim must be able to engage all pro-survival Bcl-2 family members for efficient tumor suppression. Oncogene, 2012, 31, 3392-3396. | 5.9 | 20 |
| 30 | Controlling TRAIL-mediated caspase-3 activation. Leukemia, 2004, 18, 1578-1580. | 7.2 | 10 |
| 31 | Deglycosylated bleomycin induces apoptosis in lymphoma cell via c-jun NH2-terminal kinase but not reactive oxygen species. Biochemical Pharmacology, 2007, 74, 1445-1455. | 4.4 | 9 |
| 32 | Longitudinal Monitoring of Intra-Tumoural Heterogeneity Using Optical Barcoding of Patient-Derived Colorectal Tumour Models. Cancers, 2022, 14, 581. | 3.7 | 4 |
| 33 | Computational Screening of Anti-Cancer Drugs Identifies a New BRCA Independent Gene Expression Signature to Predict Breast Cancer Sensitivity to Cisplatin. Cancers, 2022, 14, 2404. | 3.7 | 2 |
| 34 | MicroRNAs and lymphocyte homeostasis: Dangerous eggs in a single basket. Immunology and Cell Biology, 2008, 86, 387-388. | 2.3 | 1 |
| 35 | Apoptosis and Cell Survival in the Immune System. , 0, , 333-349. | | 0 |
| 36 | PG 7.02 BCL-2: a new therapeutic target in estrogen receptor-positive breast cancer?. Breast, 2015, 24, S12. | 2.2 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Elementary: breast cancer culprits leave their signatures on the double helix. <i>Cell Death and Differentiation</i> , 2016, 23, 1577-1578. | 11.2 | 0 |
| 38 | MA27.09 Dual Inhibition of BCL-XL and MCL-1 is Required to Induce Tumour Regression in Lung Squamous Cell Carcinomas Sensitive to FGFR Inhibition. <i>Journal of Thoracic Oncology</i> , 2018, 13, S457. | 1.1 | 0 |
| 39 | The role of BH3-only protein Bim extends beyond inhibiting Bcl-2-like prosurvival proteins. <i>Journal of Experimental Medicine</i> , 2009, 206, i19-i19. | 8.5 | 0 |
| 40 | Destruction of tumor vasculature and abated tumor growth upon VEGF blockade is driven by proapoptotic protein Bim in endothelial cells. <i>Journal of Cell Biology</i> , 2011, 193, i14-i14. | 5.2 | 0 |
| 41 | Abstract P2-09-01: Targeting BCL-2 with the BH3 mimetic ABT-199 in ER-positive breast cancer. , 2013, , . | | 0 |
| 42 | Abstract IA19: Targeting the BCL-2 family in breast cancer. , 2016, , . | | 0 |
| 43 | Abstract PD9-05: The importance of the metastatic biopsy: Clinical and translational relevance in a real world series of patients with metastatic breast cancer. , 2019, , . | | 0 |